Regulus Therapeutics Stock Price, News & Analysis (NASDAQ:RGLS)

$0.92 -0.02 (-2.13 %)
(As of 11/20/2017 10:22 AM ET)
Previous Close$0.94
Today's Range$0.90 - $0.99
52-Week Range$0.79 - $3.10
Volume3.41 million shs
Average Volume887,570 shs
Market Capitalization$95.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:RGLS
  • CUSIP: 75915K10
  • Web: www.regulusrx.com
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 6.77%
  • Quick Ratio: 6.77%
Sales & Book Value:
  • Annual Sales: $1.19 million
  • Price / Sales: 80.37
  • Book Value: $1.06 per share
  • Price / Book: 0.87
Profitability:
  • Trailing EPS: ($1.34)
  • Net Income: ($81,830,000.00)
  • Net Margins: -107,606.96%
  • Return on Equity: -189.71%
  • Return on Assets: -92.92%
Misc:
  • Employees: 97
  • Outstanding Shares: 103,960,000
 

Frequently Asked Questions for Regulus Therapeutics (NASDAQ:RGLS)

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings data on Tuesday, August, 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.50 million. Regulus Therapeutics had a negative net margin of 107,606.96% and a negative return on equity of 189.71%. View Regulus Therapeutics' Earnings History.

When will Regulus Therapeutics make its next earnings announcement?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Regulus Therapeutics.

Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2017?

6 brokers have issued 12-month price targets for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $4.00. On average, they anticipate Regulus Therapeutics' stock price to reach $2.88 in the next year. View Analyst Ratings for Regulus Therapeutics.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it." (11/14/2017)
  • 2. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (10/10/2017)
  • 3. Wedbush analysts commented, "RGLS reported Q4/FY16 revenues of $0.02MM/$1.2MM vs. consensus estimates of $0.2MM/$1.4MM and GAAP EPS (loss) of $(0.38)/$(1.55) vs. consensus estimates of $(0.34)/$(1.52). RGLS ended 2016 with cash and cash equivalents of $76.1MM, which we project to provide cash runway into mid:18 aligned with guidance... Following completion of the multiple ascending dose (MAD) study of RG-012 in healthy volunteers in Q2:17, RGLS is planning to initiate a Phase 1/2 renal biopsy study in AS patients that will evaluate RG-012 tissue PK, target engagement, and effects on disease biomarkers. We believe positive results in-line with RGLS' preclinical data could be indicative of future success." (3/6/2017)
  • 4. Cowen and Company analysts commented, "Regulus reported Q4 earnings and provided a pipeline update." (3/3/2017)
  • 5. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on RGLS stock, but we are lowering our PT by $4 to $7, as a result of a reduction in our pTS estimate for the RG-101 program from 50% to 25%. We believe that "platform buyers" could still be attracted to the stock, but that investors seeking commercial proof of concept may have been put somewhat at bay given the delay in the FDA lift of the clinical trial hold for RG-101 as a treatment for infection with the HCV." (3/3/2017)

Who are some of Regulus Therapeutics' key competitors?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Chairman of the Board (Age 68)
  • Joseph P. Hagan, President, Chief Executive Officer, Principal Executive Officer, Director (Age 48)
  • Daniel Chevallard, Chief Financial Officer, Principal Financial and Accounting Officer
  • Mark Deeg, Chief Medical Officer
  • B. Lynne Parshall J.D., Director (Age 63)
  • Douglas E. Williams Ph.D., Director (Age 59)
  • David Baltimore Ph.D., Independent Director (Age 79)
  • Mark G. Foletta CPA, Independent Director (Age 55)
  • William H. Rastetter Ph.D., Independent Director (Age 68)

Who owns Regulus Therapeutics stock?

Regulus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (10.59%), South Dakota Investment Council (1.75%), Candriam Luxembourg S.C.A. (0.58%), Wells Fargo & Company MN (0.47%) and Victory Capital Management Inc. (0.27%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?

Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Regulus Therapeutics.

Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?

Regulus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Candriam Luxembourg S.C.A., South Dakota Investment Council and Victory Capital Management Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy Regulus Therapeutics stock?

Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of Regulus Therapeutics stock can currently be purchased for approximately $0.92.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $95.64 million and generates $1.19 million in revenue each year. The biopharmaceutical company earns ($81,830,000.00) in net income (profit) each year or ($1.34) on an earnings per share basis. Regulus Therapeutics employs 97 workers across the globe.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10614 Science Center Dr, SAN DIEGO, CA 92121-1150, United States. The biopharmaceutical company can be reached via phone at +1-858-2026300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Regulus Therapeutics (NASDAQ:RGLS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $2.88 (212.50% upside)

Consensus Price Target History for Regulus Therapeutics (NASDAQ:RGLS)

Price Target History for Regulus Therapeutics (NASDAQ:RGLS)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
8/7/2017WedbushReiterated RatingOurperform$4.00MediumView Rating Details
8/2/2017Chardan CapitalDowngradeBuy -> NeutralLowView Rating Details
6/12/2017BMO Capital MarketsSet Price TargetHold$1.00LowView Rating Details
3/3/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/3/2017Cantor FitzgeraldLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
1/30/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Regulus Therapeutics (NASDAQ:RGLS)

Earnings by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Earnings History by Quarter for Regulus Therapeutics (NASDAQ RGLS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018        
8/1/2017Q2 2017($0.31)($0.41)$0.02 million$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.38)$0.20 million$0.02 millionViewListenView Earnings Details
8/2/2016Q216($0.38)($0.40)$0.50 million$0.48 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)$2.25 million$0.49 millionViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$3.57 million$1.87 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)$3.38 million$4.20 millionViewListenView Earnings Details
2/18/2015($0.21)($0.47)$2.24 million$4.22 millionViewListenView Earnings Details
11/5/2014($0.23)($0.23)$2.76 million$1.08 millionViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.20 million$0.74 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)$3.80 million$1.63 millionViewN/AView Earnings Details
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
2017 EPS Consensus Estimate: ($0.79)
2018 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.13)($0.13)($0.13)
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Regulus Therapeutics (NASDAQ RGLS)

Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 40.80%
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Insider Trades by Quarter for Regulus Therapeutics (NASDAQ RGLS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Daniel R ChevallardCFOBuy54,945$0.91$49,999.95View SEC Filing  
7/25/2017Joseph P HaganInsiderBuy219,780$0.91$199,999.80View SEC Filing  
7/25/2017William H RastetterDirectorBuy274,725$0.91$249,999.75View SEC Filing  
3/22/2017Stelios PapadopoulosDirectorBuy500,000$1.22$610,000.00View SEC Filing  
3/7/2017William H RastetterDirectorBuy250,000$1.15$287,500.00View SEC Filing  
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regulus Therapeutics (NASDAQ RGLS)

Source:
DateHeadline
Regulus Therapeutics Inc. (RGLS) Receives Consensus Rating of "Hold" from AnalystsRegulus Therapeutics Inc. (RGLS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 16 at 11:02 AM
Regulus Therapeutics Inc. (RGLS) Earns Hold Rating from Needham & Company LLCRegulus Therapeutics Inc. (RGLS) Earns Hold Rating from Needham & Company LLC
www.americanbankingnews.com - November 14 at 10:26 PM
Regulus Therapeutics Inc. to Host Earnings CallRegulus Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:26 PM
Regulus Reports Third Quarter 2017 Financial Results and Recent EventsRegulus Reports Third Quarter 2017 Financial Results and Recent Events
finance.yahoo.com - November 9 at 12:26 PM
Regulus reports 3Q lossRegulus reports 3Q loss
finance.yahoo.com - November 9 at 12:26 PM
Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 12:26 PM
Regulus Therapeutics Inc. (RGLS) Issues Quarterly  Earnings ResultsRegulus Therapeutics Inc. (RGLS) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 6:35 PM
Regulus Therapeutics Inc. (RGLS) Set to Announce Earnings on TuesdayRegulus Therapeutics Inc. (RGLS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - November 1 at 8:09 AM
Head-To-Head Survey: Regulus Therapeutics (RGLS) vs. The CompetitionHead-To-Head Survey: Regulus Therapeutics (RGLS) vs. The Competition
www.americanbankingnews.com - November 1 at 1:20 AM
Regulus Therapeutics Inc. (RGLS) to Release Earnings on MondayRegulus Therapeutics Inc. (RGLS) to Release Earnings on Monday
www.americanbankingnews.com - October 23 at 9:40 AM
Regulus Therapeutics Inc. (RGLS) Receives Average Recommendation of "Hold" from AnalystsRegulus Therapeutics Inc. (RGLS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 11:02 AM
Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in SessionRegulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
finance.yahoo.com - October 3 at 11:41 AM
Head-To-Head Contrast: Regulus Therapeutics (RGLS) and Codexis (CDXS)Head-To-Head Contrast: Regulus Therapeutics (RGLS) and Codexis (CDXS)
www.americanbankingnews.com - September 30 at 6:15 PM
Regulus Therapeutics Inc. (RGLS) Given Consensus Recommendation of "Hold" by AnalystsRegulus Therapeutics Inc. (RGLS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 27 at 10:36 AM
Regulus Therapeutics Inc. (RGLS) Sees Significant Increase in Short InterestRegulus Therapeutics Inc. (RGLS) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 16 at 1:20 AM
Regulus to Present at the 2017 Wells Fargo Healthcare ConferenceRegulus to Present at the 2017 Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 9:25 AM
Regulus Therapeutics Inc. (RGLS) Short Interest UpdateRegulus Therapeutics Inc. (RGLS) Short Interest Update
www.americanbankingnews.com - August 29 at 1:06 AM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - NasdaqAre Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - Nasdaq
www.nasdaq.com - August 26 at 8:50 AM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
finance.yahoo.com - August 25 at 10:53 AM
Brokers Issue Forecasts for Regulus Therapeutics Inc.s Q3 2017 Earnings (NASDAQ:RGLS)Brokers Issue Forecasts for Regulus Therapeutics Inc.'s Q3 2017 Earnings (NASDAQ:RGLS)
www.americanbankingnews.com - August 9 at 7:28 AM
Regulus to Present at the 2017 Wedbush PacGrow Healthcare ConferenceRegulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 6:56 AM
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by BrokeragesRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 8 at 11:04 AM
Regulus Therapeutics Inc. (RGLS) Earns "Ourperform" Rating from WedbushRegulus Therapeutics Inc. (RGLS) Earns "Ourperform" Rating from Wedbush
www.americanbankingnews.com - August 7 at 11:20 AM
Regulus Therapeutics (RGLS) Hold Rating Reaffirmed at Needham & Company LLCRegulus Therapeutics' (RGLS) Hold Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - August 2 at 4:38 PM
Regulus Therapeutics Inc. (RGLS) Releases Quarterly  Earnings Results, Misses Estimates By $0.10 EPSRegulus Therapeutics Inc. (RGLS) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - August 2 at 12:40 PM
Regulus Therapeutics (RGLS) CEO Jay Hagan on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaRegulus Therapeutics' (RGLS) CEO Jay Hagan on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 2 at 7:11 AM
Investor Network: Regulus Therapeutics Inc. to Host Earnings CallInvestor Network: Regulus Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 7:10 AM
Regulus Reports Second Quarter 2017 Financial Results and Recent EventsRegulus Reports Second Quarter 2017 Financial Results and Recent Events
finance.yahoo.com - August 2 at 7:10 AM
Regulus reports 2Q lossRegulus reports 2Q loss
finance.yahoo.com - August 2 at 7:10 AM
Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMTEdited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT
finance.yahoo.com - August 2 at 7:10 AM
Regulus Therapeutics Inc. Forecasted to Earn Q3 2017 Earnings of ($0.10) Per Share (RGLS)Regulus Therapeutics Inc. Forecasted to Earn Q3 2017 Earnings of ($0.10) Per Share (RGLS)
www.americanbankingnews.com - July 31 at 7:39 AM
Regulus Therapeutics Inc. (NASDAQ:RGLS) to Release Earnings on TuesdayRegulus Therapeutics Inc. (NASDAQ:RGLS) to Release Earnings on Tuesday
www.americanbankingnews.com - July 27 at 3:04 PM
Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017
finance.yahoo.com - July 26 at 6:46 AM
Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional SharesRegulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 26 at 6:46 AM
Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of SharesRegulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares
finance.yahoo.com - July 26 at 6:46 AM
Regulus Therapeutics Inc. (RGLS) Insider Purchases $199,999.80 in StockRegulus Therapeutics Inc. (RGLS) Insider Purchases $199,999.80 in Stock
www.americanbankingnews.com - July 25 at 7:51 PM
Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Daniel R. Chevallard Buys 54,945 SharesRegulus Therapeutics Inc. (NASDAQ:RGLS) CFO Daniel R. Chevallard Buys 54,945 Shares
www.americanbankingnews.com - July 25 at 7:51 PM
William H. Rastetter Acquires 274,725 Shares of Regulus Therapeutics Inc. (RGLS) StockWilliam H. Rastetter Acquires 274,725 Shares of Regulus Therapeutics Inc. (RGLS) Stock
www.americanbankingnews.com - July 25 at 7:28 PM
DryShips, CH Robinson Slide into Thursdays 52-Week Low Club - 24/7 Wall St.DryShips, CH Robinson Slide into Thursday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - July 20 at 8:49 PM
28 Stocks Moving In Thursdays Pre-Market Session - Benzinga28 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - July 20 at 3:48 PM
Regulus Therapeutics (RGLS) Announces 44M Share Common Offering - StreetInsider.comRegulus Therapeutics (RGLS) Announces 44M Share Common Offering - StreetInsider.com
www.streetinsider.com - July 20 at 3:48 PM
Regulus Announces Commencement of Public Offering of Common StockRegulus Announces Commencement of Public Offering of Common Stock
finance.yahoo.com - July 20 at 7:11 AM
Regulus Announces Pricing of Public Offering of Common StockRegulus Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - July 20 at 7:11 AM
Regulus Therapeutics (RGLS) Promotes Mark Deeg to CMORegulus Therapeutics (RGLS) Promotes Mark Deeg to CMO
www.streetinsider.com - June 14 at 12:37 AM
Regulus Therapeutics (RGLS) Promotes Mark Deeg to CMO - StreetInsider.comRegulus Therapeutics (RGLS) Promotes Mark Deeg to CMO - StreetInsider.com
www.streetinsider.com - June 13 at 7:36 PM
BUZZ-U.S. STOCKS ON THE MOVE-GE, Apple, CoherusBUZZ-U.S. STOCKS ON THE MOVE-GE, Apple, Coherus
www.nasdaq.com - June 12 at 8:47 AM
Aptuit anuncia un acuerdo de proveedor estratégico con Regulus ... - PR Newswire (Comunicado de prensa)Aptuit anuncia un acuerdo de proveedor estratégico con Regulus ... - PR Newswire (Comunicado de prensa)
www.prnewswire.com - June 8 at 8:38 AM
Regulus Therapeutics (RGLS) & Aptuit LLC Announce Strategic Provider Agreement - StreetInsider.comRegulus Therapeutics (RGLS) & Aptuit LLC Announce Strategic Provider Agreement - StreetInsider.com
www.streetinsider.com - June 8 at 8:38 AM
EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics ...EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics ...
www.nasdaq.com - May 20 at 11:44 AM

Social Media

Financials

Chart

Regulus Therapeutics (NASDAQ RGLS) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.